Literature DB >> 18285476

Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype.

Brian T Tsuji1, Christof von Eiff, Pamela A Kelchlin, Alan Forrest, Patrick F Smith.   

Abstract

The in vitro bactericidal activities of vancomycin against Staphylococcus aureus hemB mutants displaying the small-colony-variant phenotype and their parental strains were evaluated. Vancomycin killing activities against hemB mutants were markedly attenuated, demonstrating approximately 50% less effect, a result which was well described by a Hill-type pharmacodynamic model.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18285476      PMCID： PMC2292514          DOI： 10.1128/AAC.01254-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections.

Authors:  Richard A Proctor; Christof von Eiff; Barbara C Kahl; Karsten Becker; Peter McNamara; Mathias Herrmann; Georg Peters
Journal:  Nat Rev Microbiol       Date:  2006-04       Impact factor: 60.633

2.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

3.  Transcription of virulence factors in Staphylococcus aureus small-colony variants isolated from cystic fibrosis patients is influenced by SigB.

Authors:  Hélène Moisan; Eric Brouillette; Christian Lebeau Jacob; Philippe Langlois-Bégin; Sophie Michaud; François Malouin
Journal:  J Bacteriol       Date:  2006-01       Impact factor: 3.490

4.  A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly.

Authors:  C von Eiff; C Heilmann; R A Proctor; C Woltz; G Peters; F Götz
Journal:  J Bacteriol       Date:  1997-08       Impact factor: 3.490

5.  Triclosan resistance in methicillin-resistant Staphylococcus aureus expressed as small colony variants: a novel mode of evasion of susceptibility to antiseptics.

Authors:  Roger Bayston; Waheed Ashraf; Toni Smith
Journal:  J Antimicrob Chemother       Date:  2007-03-02       Impact factor: 5.790

6.  Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis.

Authors:  B Kahl; M Herrmann; A S Everding; H G Koch; K Becker; E Harms; R A Proctor; G Peters
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

7.  Increased expression of clumping factor and fibronectin-binding proteins by hemB mutants of Staphylococcus aureus expressing small colony variant phenotypes.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; William L Kelley; Daniel P Lew; Jacques Schrenzel; Richard A Proctor; Peter J McNamara; G Peters; Christof Von Eiff
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Small colony variants in staphylococcal infections: diagnostic and therapeutic implications.

Authors:  R A Proctor; G Peters
Journal:  Clin Infect Dis       Date:  1998-09       Impact factor: 9.079

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants.

Authors:  Nicole Baumert; Christof von Eiff; Franziska Schaaff; Georg Peters; Richard A Proctor; Hans-Georg Sahl
Journal:  Microb Drug Resist       Date:  2002       Impact factor: 3.431
View more
  32 in total

1.  Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Authors:  Brian T Tsuji; James Fisher; Raheal Boadi-Yeboah; Patricia N Holden; Sanjay Sethi; Melinda M Pettigrew; Timothy F Murphy
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Vancomycin and daptomycin pharmacodynamics differ against a site-directed Staphylococcus epidermidis mutant displaying the small-colony-variant phenotype.

Authors:  Marina Wu; Christof von Eiff; Nahed Al Laham; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections.

Authors:  Jill M Butterfield; Brian T Tsuji; Jack Brown; Elizabeth Dodds Ashley; Dwight Hardy; Kristen Brown; Alan Forrest; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

4.  Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Authors:  Neang S Ly; Zackery P Bulman; Jürgen B Bulitta; Christopher Baron; Gauri G Rao; Patricia N Holden; Jian Li; Mark D Sutton; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa.

Authors:  Neang S Ly; Jenny Yang; Jurgen B Bulitta; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

Review 6.  Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.

Authors:  Barbara C Kahl; Karsten Becker; Bettina Löffler
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

7.  Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.

Authors:  Zackery P Bulman; Mark D Sutton; Neang S Ly; Jurgen B Bulitta; Patricia N Holden; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

8.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

9.  Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection.

Authors:  Wei Gao; Kyra Chua; John K Davies; Hayley J Newton; Torsten Seemann; Paul F Harrison; Natasha E Holmes; Hyun-Woo Rhee; Jong-In Hong; Elizabeth L Hartland; Timothy P Stinear; Benjamin P Howden
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

10.  Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design.

Authors:  Cornelia B Landersdorfer; Neang S Ly; Hongmei Xu; Brian T Tsuji; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.